Drug makers face tougher rules on human placenta drugs

The Korea Food and Drug Administration (KFDA) said it will tighten rules on a human placenta drug as part of efforts to ensure its safety and efficacy.

To bring the finished placenta products by pharmaceutical firms under closer scrutiny, they will be produced using virus-free placenta bulk materials subject to the drug master file (DMF) system from this July, the KFDA said.

The DMF syste...